Amyvid maker expresses disappointment with CMS ruling

07/7/2013 | (free registration)

Avid Radiopharmaceuticals President and CEO Daniel Skovronsky expressed frustration with the CMS draft decision to provide limited coverage of PET beta-amyloid imaging scans for patients with dementia or neurodegenerative disease. "CMS appears to be challenging the value of an adjunctive tool that can assist physicians in making a more informed diagnosis for patients with cognitive impairment. Restricting coverage could hinder a timely and accurate diagnosis," Skovronsky said in a statement. The agency agreed to cover only one scan per patient under certain terms, saying there is "insufficient" evidence of the test's health benefits.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA